Cephalon to acquire North American Amrix rights

2 September 2007

Italian drugmaker Eurand NV says that US biopharmaceutical firm Cephalon has signed an agreement to acquire North American rights to Amrix (cyclobenzapine HCl extended-release capsules) from fellow US company ECR Pharmaceuticals. The drug is a muscle relaxant developed by Eurand using its proprietary Diffucaps technology.

Eurand, as the licensor and exclusive manufacturer of the product, will now work with Cephalon to support the commercialization of the product in the USA, and will receive royalty payments based on sales. ECR obtained US approval of Amrix for short-term use as an adjunct to rest and physical therapy in the treatment of muscle spasm associated with acute, painful musculoskeletal conditions, earlier this year.

Gearoid Faherty, Eurand chief executive, said: "we would like to recognize the efforts of our partner, ECR, in obtaining regulatory approval for Amrix and look forward to working with Cephalon in commercialization of the product in the United States." Financial terms of the deal were not provided.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight